ПУРИНЕРГИЧЕСКАЯ РЕГУЛЯЦИЯ ОСНОВНЫХ ФИЗИОЛОГИЧЕСКИХ И ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ
https://doi.org/10.15789/1563-0625-2018-4-463-476
Аннотация
В последние годы ведется активное изучение значимости пуринергического сигналинга в патогенезе широкого спектра заболеваний и патологических состояний, к числу которых относятся регуляция инфекционного и неинфекционного воспаления, опухолевого роста и метастазирования, реакций отторжения трансплантата, аутоиммунных заболеваний, кальцификации элементов сердечно-сосудистой системы и т.д. Было показано, что пуринергическая система осуществляет тонкую регуляцию функций клеток иммунной системы аналогично цитокиновой и хемокиновой секреции, удалению внутриклеточных патогенов и механизмов клеточной гибели. Основываясь на понимании механизмов развития этих состояний, в том числе и участии пуринергической системы в их регуляции, разрабатываются новые подходы к терапии и профилактике. Анализу достижений последнего времени в участии пуринергической регуляции в основных патологических состояниях и заболеваниях, а также трендам в разработке терапевтических подходов на основании полученных знаний посвящен данный обзор.
При поддержке: РФФИ
Об авторах
А. С. Головкин
ФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова»
Россия
Россия
д.м.н., руководитель группы, Институт молекулярной биологии и генетики,
197341, Санкт-Петербург, ул. Аккуратова, 2
И. А. Асадуллина
ФГБНУ «Институт экспериментальной медицины»
Россия
Россия
младший научный сотрудник отдела иммунологии,
Санкт-Петербург
И. В. Кудрявцев
ФГБНУ «Институт экспериментальной медицины»;
ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения РФ
Россия
Россия
к.б.н., старший научный сотрудник отдела иммунологии;
доцент кафедры иммунологии,
Санкт-Петербург
Список литературы
1. Головкин А.С., Кудрявцев И.В., Серебрякова М.К., Малашичева А.Б., Шишкова А.А., Жидулева Е.В., Иртюга О.Б., Моисеева О.М. Кальциноз аортального клапана: субпопуляционный состав циркулирующих T-клеток и пуринергическая регуляция // Российский иммунологический журнал, 2016, Т. 10 (19), № 2 (1). С. 189-191. [Golovkin A.S, Kudryavtsev I.V., Serebryakova M.K., Malashicheva A.B., Shishkova A.A., Zhiduleva E.V., Irtuga O.B., Moiseeva O.B. Calcified aortic stenosis: peripheral T-cells subpopulations and purinergic regulation. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2016, Vol. 10 (19), no. 2 (1), pp. 189-191. (In Russ.)]
2. Матвеева В.Г., Головкин А.С., Чернова М.Н., Кудрявцев И.В., Иванов С.В., Григорьев Е.В. Влияние цитозольной фракции кардиомиоцитов и липополисахарида на функцию моноцитов // Медицинская иммунология, 2013. Т. 15, № 5. С. 439-448. [Matveeva V.G., Golovkin A.S., Chernova M.N., Kudryavtsev I.V., Ivanov S.V., Grigoriev E.V. Effects of myocardial cytosolic fraction and lipopolysaccharide upon monocytic functions. Meditsinskaya immunologiya = Medical Immunology (Russia), 2013, Vol. 15, no. 5, pp. 439-448. (In Russ.)] doi: 10.15789/1563-0625-2013-5-439-448.
3. Матвеева В.Г., Головкин А.С., Антонова Л.В., Кудрявцев И.В., Иванов С.В., Григорьев Е.В., Артымук Н.В., Тришкин А.Г. Влияние продуктов механического повреждения миокарда, Lps и их сочетания на эндотелиальные клетки из пупочной вены человека // Медицинская иммунология, 2014. Т. 16, № 4. С. 361-366. [Matveeva V.G., Golovkin A.S., Antonova L.V., Kudryavtsev I.V., Ivanov S.V., Grigoriev E.V., Artymuk N.V., Trishkin A.G., Bikmetova E.S. Impact of mechanical myocardial injury products, Lps and their combination on human umbilical vein endothelial cells. Meditsinskaya immunologiya = Medical Immunology (Russia), 2014, Vol. 16, no. 4, pp. 361-366. (In Russ.)] doi: 10.15789/1563-0625-2014-4-361-366.
4. Abbracchio M.P., Burnstock G., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C., Knight G.E., Fumagalli M., Gachet C., Jacobson K.A., Weisman G.A. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev., 2006, Vol. 58, no. 3, pp. 281-341.
5. Antonioli L., Pacher P., Vizi E.S., Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med., 2013, Vol. 19, no. 6, pp. 355-367.
6. Antonioli L., Yegutkin G.G., Pacher P., Blandizzi C., Haskó G. Anti-CD73 in cancer immunotherapy: Awakening new opportunities. Trends in Cancer, 2016, Vol. 2, no. 2, pp. 95-109.
7. Barbarash L., Kudryavtsev I., Rutkovskaya N., Golovkin A. T сell response in patients with implanted biological and mechanical prosthetic heart valves. Mediat. Inflammation, 2016, Vol. 2016, Article ID 1937564, 12 p. doi.: 10.1155/2016/1937564.
8. Barletta K.E., Ley K., Mehrad B. Regulation of neutrophil function by adenosine. Arterioscler. Thromb. Vasc. Biol., 2012, Vol. 32, no. 4, pp. 856-864.
9. Bhattarai S., Freundlieb M., Pippel J., Meyer A., Abdelrahman A., Lee S., Zimmermann H., Yegutkin G.G., Sträter N., El-Tayeb A., Müller C.E. Supporting Information α, β-Methylene-ADP (AOPCP) derivatives and analogs: development of potent and selective ecto-5′-nucleotidase (CD73) inhibitors. J. Med. Chem., 2015, Vol. 58, no. 15, pp. 1-25.
10. Blume C., Felix A., Shushakova N., Gueler F., Falk C.S., Haller H., Schrader J. Autoimmunity in CD73/ Ecto-5′-nucleotidase deficient mice induces renal injury. Câmara NOS, ed. PLoS ONE, 2012, Vol. 7, no. 5, e37100. doi:10.1371/journal.pone.0037100.
11. Borsellino G., Kleinewietfeld M., di Mitri D., Sternjak A., Diamantini A., Giometto R., Höpner S., Centonze D., Bernardi G., Dell’Acqua M.L., Rossini P.M., Battistini L., Rötzschke O., Falk K. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood, 2007, Vol. 110, no. 4, pp. 1225-1232.
12. Botta Gordon-Smith S., Ursu S., Eaton S., Moncrieffe H., Wedderburn L.R. Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis. Arthritis Rheumatol., 2015, Vol. 67, no. 2, pp. 545-554.
13. Bours M.J.L., Swennen E.L.R., di Virgilio F., Cronstein B.N., Dagnelie P.C. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther., 2006, Vol. 112, no. 2, pp. 358-404.
14. Burnstock G. Purinergic nerves. Pharmacol. Rev., 1972, Vol. 24, no. 3, pp. 509-581.
15. Bynoe M.S., Waickman A.T., Mahamed D.A., Mueller C., Mills J.H., Czopik A. CD73 is critical for the resolution of murine colonic inflammation. J. Biomed. Biotechnol., 2012, Vol. 2012, pp. 1-13.
16. Chen J.F., Eltzschig, H.K., Fredholm BB. Adenosine receptors as drug targets – what are the challenges? Nat. Rev. Drug. Discov., 2013, Vol. 12, no. 4, pp. 265-286.
17. Chrobak P., Charlebois R., Rejtar P., El Bikai R., Allard B., Stagg J. CD73 plays a protective role in collageninduced arthritis. J. Immunol., 2015, Vol. 194, no. 6, pp. 2487-2492.
18. Colgan S.P., Colgan S.P., Eltzschig H.K., Eckle T., Thompson L.F. Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signalling, 2006, no. 2 (2), pp. 351-360.
19. Cote N., Husseini D.E., Pepin A., Guauque-Olarte S., Ducharme V., Bouchard-Cannon P., Audet A., Fournier D., Gaudreault N., Derbali H., McKee M.D., Simard C., Després J.P., Pibarot P., Bossé Y., Mathieu P. ATP acts as a survival signal and prevents the mineralization of aortic valve. J. Mol. Cell. Cardiol., 2012, Vol. 52, no. 5, pp. 1191-1202.
20. Coutinho-Silv R., Knight G.E., Burnstock G. Impairment of the splenic immune system in P2X(2)/P2X(3) knockout mice. Immunobiology, 2005, Vol. 209, no. 9, pp. 661-668.
21. Cronstein B.N., Montesinos M.C., Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc. Natl. Acad. Sci. USA, 1999, Vol. 96, no. 11, pp. 6377-6381.
22. Cruz C.M., Rinna A., Forman H.J., Ventura A.L., Persechini P.M., Ojcius D.M. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J. Biol. Chem., 2007, Vol. 282, no. 5, pp. 2871-2879.
23. Csóka B., Himer L., Selmeczy Z., Vizi E.S., Pacher P., Ledent C., Deitch E.A., Spolarics Z., Németh Z.H., Haskó G. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J., 2008, Vol. 22, no. 10, pp. 3491-3499.
24. Day Y.-J., Huang L., McDuffie M.J., Rosin D.L., Ye H., Chen J.-F., Schwarzschild M.A., Fink J.S., Linden J., Okusa M.D. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest., 2003, Vol. 112, no. 6, pp. 883-891.
25. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., Chen J.-F., Enjyoji K., Linden J., Oukka M., Kuchroo V.K., Strom T.B., Robson S.C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med., 2007, Vol. 204, no. 6, pp. 1257-1265.
26. Dwyer K.M., Deaglio S., Gao W., Friedman D., Strom T.B., Robson S.C. CD39 and control of cellular immune responses. Purinergic Signal, 2007, Vol. 3, no. 1-2, pp. 171-180.
27. Dwyer K.M., Hanidziar D., Putheti P., Hill P.A., Pommey S., McRae J.L., Winterhalter A., Doherty G., Deaglio S., Koulmanda M., Gao W., Robson S.C., Strom T.B. Expression of CD39 by human peripheral blood CD4+CD25+ T cells denotes a regulatory memory phenotype. Am. J. Transplant., 2010, Vol. 10, no. 11, pp. 2410-2420.
28. Eltzschig H.K., Thompson L.F., Karhausen J., Cotta R.J., Ibla J.C., Robson S.C., Colgan S.P. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood, 2004, Vol. 104. no. 13, pp. 3986-3992.
29. Faas M.M., Sáez T., de Vos P. Extracellular ATP and adenosine: the Yin and Yang in immune responses? Mol. Aspects Med., 2017, Vol. 55, pp. 9-19.
30. Fish R.S., Klootwijk E., Tam F.W.K., Kleta R., Wheeler D.C., Unwin R.J., Norman J. ATP and arterial calcification. Eur. J. Clin. Invest., 2013, Vol. 43, pp. 405-412.
31. Fishman P., Bar-Yehuda S., Liang B.T., Jacobson K. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug. Discov. Today, 2012, Vol. 17, no. 7-8, pp. 359-366.
32. Fleisch H., Schibler D., Maerki J. F.I. Inhibition of aortic calcification by means of pyrophosphate and polyphosphates. Nature, 1965, Vol. 207, pp. 1300-1301.
33. Franceschini A., Capece M., Chiozzi P., Falzoni S., Sanz J.M., Sarti A.C., Bonora M., Pinton P., Di Virgilio F. The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein. FASEB J., 2015, Vol. 29, no. 6, pp. 2450-2461.
34. Gallos G. A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis. AJP Ren. Physiol., 2005, Vol. 289, no. 2, pp. F369-F376.
35. Gibson D.J., Elliott L., McDermott E., Tosetto M., Keegan D., Byrne K., Martin S.T., Rispens T., Cullen G., Mulcahy H.E., Cheifetz A.S., Moss A.C., Robson S.C., Doherty G.A., Ryan E.J. Heightened expression of CD39 by regulatory T lymphocytes Is associated with therapeutic remission in inflammatory bowel disease. Inflamm. Bowel Dis., 2015, Vol. 21, no. 12, pp. 2806-2814.
36. Giménez-Llort L., Fernández-Teruel A., Escorihuela R.M., Fredholm B.B., Tobeña A., Pekny M., Johansson B. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci., 2002, Vol. 16, no. 3, pp. 547-550.
37. Grenz A., Zhang H., Hermes M., Eckle T., Klingel K., Huang D.Y., Muller C.E., Robson S.C., Osswald H., Eltzschig H.K. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J., 2007, Vol. 21, pp. 2863-2873.
38. Grol M.W., Panupinthu N., Korcok J., Sims S.M. Expression, signalling, and function of P2X7 receptors in bone. Purinergic Signal, 2009, Vol. 5, pp. 205-221.
39. Hart M.L., Gorzolla I.C., Schittenhelm J., Robson S.C., Eltzschig H.K. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J. Immunol., 2010, Vol. 184, pp. 4017-4024.
40. Haskó G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug. Discov., 2008, Vol. 7, no. 9, pp. 759-770..
41. Heemskerk S., Masereeuw R., Moesker O., Bouw M.P.W.J.M., van der Hoeven J.G., Peters W.H.M., Russel F.G.M., Pickkers P. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit. Care Med., 2009, Vol. 37, no. 2, pp. 417-423.
42. Hill L.M., Gavala M.L., Lenertz L.Y., Bertics P.J. Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes. J. Immunol., 2010, Vol. 185, no. 5, pp. 3028-3034.
43. Horenstein A.L., Chillemi A., Zaccarello G., Bruzzone S., Quarona V., Zito A., Serra S., Malavasi F. CD38/ CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology, 2013, Vol. 2, no. 9, e26246. doi:10.4161/onci.26246.
44. Horrigan L.A., Kelly J.P., Connor T.J. Immunomodulatory effects of caffeine: Friend or foe? Pharmacol. Ther., 2006, Vol. 111, no. 3, pp. 877-892.
45. Hoskin D.W., Mader J.S., Furlong S.J., Conrad D.M., Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (review). Int. J. Oncol., 2008, Vol. 32, pp. 527-535.
46. Idzko M., Ferrari D., Eltzschig H.K. Nucleotide signalling during inflammation. Nature, 2014, Vol. 509, no. 7500, pp. 310-317.
47. Johansson B., Halldner L., Dunwiddie T.V., Masino S.A., Poelchen W., Giménez-Llort L., Escorihuela R.M., Fernández-Teruel A., Wiesenfeld-Hallin Z., Xu X.J., Hårdemark A., Betsholtz C., Herlenius E., Fredholm B.B. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc. Natl. Acad. Sci. USA, 2001, Vol. 98, no. 16, pp. 9407-9412.
48. Junger W.G. Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol., 2011, Vol. 11, no. 3, pp. 201-212.
49. Kaniewska E., Sielicka A., Sarathchandra P., Pelikant-Małecka I., Olkowicz M., Słomińska E.M., Chester A.H., Yacoub M.H., Smoleński RT. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5′-nucleotidase (CD73) in pig aortic valves. Nucleosides, Nucleotides and Nucleic Acids, 2014, Vol. 33, no. 4-6, pp. 305-312.
50. Kanneganti T.D., Lamkanfi M., Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity, 2007, Vol. 27, no. 4, pp. 549-559.
51. Kauffenstein G., Fürstenau C.R., D’Orleans-Juste P., Sevigny J. The ecto-nucleotidase NTPDase1 differentially regulates P2Y1 and P2Y2 receptor-dependent vasorelaxation. Br. J. Pharmacol., 2010, Vol. 159, pp. 576-585.
52. Kobayashi S., Zimmermann H., Millhorn D.E. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J. Neurochem., 2001, Vol. 74, no. 2, pp. 621-632.
53. Kohler D., Eckle T., Faigle M., Grenz A., Mittelbronn M., Laucher S., Hart M.L., Robson S.C., Müller C.E., Eltzschig H.K. CD39/ectonucleoside triphosphate diphosphohy drolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation, 2007, Vol. 116, no. 19, pp. 1784-1794.
54. Koscsó B., Csóka B., Selmeczy Z., Himer L., Pacher P., Virág L., Haskó G. Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process. J. Immunol., 2012, Vol. 188, no. 1, pp. 445-453.
55. Kreth S., Ledderose C., Luchting B., Weis F., Thiel M. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock, 2010, Vol. 34, no. 1, pp. 10-16.
56. Kronlage M., Song J., Sorokin L., Isfort K., Schwerdtle T., Leipziger J., Robaye B., Conley P.B., Kim H.-C., Sargin S., Schon P., Schwab A., Hanley P.J. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal, 2010, Vol. 3, no. 132, ra55. doi: 10.1126/scisignal.2000588.
57. Whiteside T.L., Mandapathil M., Schuler P. The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr. Med. Chem., 2011, Vol. 18, no. 34, pp. 5217-5223.
58. Lazar Z., Mullner N., Lucattelli M., Ayata C., Korcan Cicko S., Yegutkin G.G., Cunto G.D., Muller T., Meyer A., Hossfeld M., Sorichter S., Horvath I., Virchow C.J., Robson S.C., Lungarella G., Idzko M. NTPDase1/ CD39 and aberrant purinergic signalling in the pathogenesis of COPD. Eur. Respir. J., 2016, Vol. 47, no. 1, pp. 254-263.
59. Lazarowski E.R. Vesicular and conductive mechanisms of nucleotide release. Purinergic Signal, 2012, Vol. 8, no. 3, pp. 359-373.
60. Ledderose C., Bao Y., Kondo Y., Fakhari M., Slubowski C., Zhang J., Junger W.G. Purinergic signaling and the immune response in sepsis: a review. Clin. Ther., 2016, Vol. 38, no. 5, pp. 1054-1065.
61. Ledderose C., Bao Y., Ledderose S., Woehrle T., Heinisch M., Yip L., Zhang J., Robson S.C., Shapiro N.I. Mitochondrial dysfunction, depleted purinergic signaling, and defective T cell vigilance and immune defense. J. Infect. Dis., 2016, Vol. 213, no. 3, pp. 456-464.
62. Lee H.T., Kim M., Joo J.D., Gallos G., Chen J.-F., Emala C.W. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2006, Vol. 291, no. 4, pp. R959-R969.
63. Lépine S., Le Stunff H., Lakatos B., Sulpice J.C., Giraud F. ATP-induced apoptosis of thymocytes is mediated by activation of P2X7 receptor and involves de novo ceramide synthesis and mitochondria. Biochim. Biophys. Acta – Mol. Cell. Biol. Lipids, 2006, Vol. 1761, no. 1, pp. 73-82.
64. Lomashvili K.A. Reduced plasma pyrophosphate levels in hemodialysis patients. J. Am. Soc. Nephrol., 2005, Vol. 16, pp. 2495-2500.
65. Mandapathil M., Lang S., Gorelik E., Whiteside T.L. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J. Immunol. Methods, 2009, Vol. 346, pp. 55-63.
66. Mandapathil M., Hilldorfer B., Szczepanski M.J., Czystowska M., Szajnik M., Ren J., Lang S., Jackson E.K., Gorelik E., Whiteside T.L. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem., 2010, Vol. 285, no. 10, pp. 7176-7186.
67. Mandapathil M., Szczepanski M.J., Szajnik M., Ren J., Jackson E.K., Johnson J.T., Gorelik E., Lang S., Whiteside T.L. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J. Biol. Chem., 2010, Vol. 285, no. 36, pp. 27571-27580.
68. Manohar M., Hirsh M.I., Chen Y., Woehrle T., Karande A.A., Junger W.G. ATP release and autocrine signaling through P2X4 receptors regulate γδ T cell activation. J. Leukoc. Biol., 2012, Vol. 92, no. 4, pp. 787-794.
69. Martin C., Leone M., Viviand X., Ayem M.-L., Guieu R. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit. Care Med., 2000, Vol. 28, no. 9, pp. 3198-3202.
70. Massie B.M., O’Connor C.M., Metra M., Ponikowski P., Teerlink J.R., Cotter G., Weatherley B.D., Cleland J.G.F., Givertz M.M., Voors A., DeLucca P., Mansoor G.A., Salerno C.M., Bloomfield D.M., Dittrich H.C. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med., 2010, Vol. 363, no. 15, pp. 1419-1428.
71. Muller-Haegele S., Muller L., Whiteside T.L. Immunoregulatory activity of adenosine and its role in human cancer progression. Expert. Rev. Clin. Immunol., 2014, Vol. 10, no. 7, pp. 897-914.
72. O'Neill W.C., Sigrist M.K., McIntyre C.W. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol. Dial. Transpl., 2010, Vol. 25, pp. 187-191.
73. Németh Z.H., Csóka B., Wilmanski J., Xu D.Z., Lu Q., Ledent C., Deitch E.A. Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J. Immunol., 2006, Vol. 176, no. 9, pp. 5616-5626.
74. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature, 2001, Vol. 414, no. 6866, pp. 916-920.
75. de Oliveira B.M., Carvalho J.L., Saldanha-Araujo F. Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression. Purinergic Signal, 2016, Vol. 12, no. 4, pp. 595-609.
76. Orriss I., Syberg S., Wang N., Robaye B., Gartland A., Jorgensen N., Arnett T., Boeynaems JM. Bone phenotypes of P2 receptor knockout mice. Front. Biosci. Sch., 2011, Vol. 3, pp. 1038-1046.
77. Orriss I.R., Burnstock G., Arnett T.R. Purinergic signalling and bone remodelling. Curr. Opin. Pharmacol., 2010, Vol. 3, pp. 322-330.
78. del Papa B., Pierini A., Sportoletti P., Baldoni S., Cecchini D., Rosati E., Dorillo E., Aureli P., Zei T., Iacucci Ostini R., Ruggeri L., Carotti A., Velardi A., Negrin R., Martelli M.F., Falzetti F., di Ianni M. The NOTCH1/CD39 axis: a Treg trip-switch for GvHD. Leukemia, 2016, Vol. 30, no. 9, pp. 1931-1934.
79. Peters E., Heemskerk S., Masereeuw R., Pickkers P. Alkaline phosphatase: a possible treatment for sepsisassociated acute kidney injury in critically Ill patients. Am. J. Kidney Dis., 2014, Vol. 63, no. 6, pp. 1038-1048.
80. Pickkers P., Heemskerk S., Schouten J., Laterre P.-F., Vincent J.-L., Beishuizen A., Jorens P.G., Spapen H., Bulitta M., Peters W.H.M., van der Hoeven J.G., Derzko A., Romaschin A. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit. Care, 2012, Vol. 41, Suppl. 7, pp. 849-855.
81. Ramakers B.P., Riksen N.P., van den Broek P., Franke B., Peters W.H.M., van der Hoeven J.G., Smits P., Pickkers P. Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury. Crit. Care, 2011, Vol. 15, no. 1, R3. doi: 10.1186/cc9400.
82. Ramakers B.P., Wever K.E., Kox M., van den Broek P.H., Mbuyi F., Rongen G., Masereeuw R., van der Hoeven J.G., Smits P., Riksen N.P., Pickkers P. How systemic inflammation modulates adenosine metabolism and adenosine receptor expression in humans in vivo. Crit. Care Med., 2012, Vol. 40, no. 9, pp. 2609-2616.
83. Reutershan J., Vollmer I., Stark S., Wagner R., Ngamsri K.C., Eltzschig H.K. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J., 2009, Vol. 23, pp. 473-482.
84. Ring S., Pushkarevskaya A., Schild H., Probst H.C., Jendrossek V., Wirsdörfer F., Ledent C., Robson S.C., Enk A.H., Mahnke K. Regulatory T cell-derived adenosine induces dendritic cell migration through the Epac-Rap1 pathway. J. Immunol., 2015, Vol. 194, no. 8, pp. 3735-3744.
85. Robson S.C., Sevigny J., Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal, 2006, Vol. 2, pp. 409-430.
86. Salvatore C.A., Tilley S.L., Latour A.M., Fletcher D.S., Koller B.H., Jacobson M.A. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem., 2000, Vol. 275, no. 6, pp. 4429-4434.
87. Sansom F.M., Newton H.J., Crikis S., Cianciotto N.P., Cowan P.J., d’Apice A.J., Hartland E.L. A bacterial ectotriphosphate diphosphohydrolase similar to human CD39 is essential for intracellular multiplication of Legionella pneumophila. Cell Microbiol., 2007, Vol. 9, pp. 1922-1935.
88. Santos R.F., Possa M.A., Bastos M.S., Guedes P.M., Almeida M.R., M.R., Demarco R., Verjovski-Almeida S., Bahia M.T., Fietto J.L. Influence of Ecto-nucleoside triphosphate diphosphohydrolase activity on Trypanosoma cruzi infectivity and virulence. PLoS Negl. Trop. Dis., 2009, Vol. 3, e387. doi: 10.1371/journal.pntd.0000387.
89. Sattler C., Steinsdoerfer M., Offers M., Fischer E., Schierl R., Heseler K., Däubener W., Seissler J. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant., 2011, Vol. 20, no. 8, pp. 1221-1230.
90. Schenk U., Frascoli M., Proietti M., Geffers R., Traggiai E., Buer J., Ricordi C., Westendorf A.M., Grassi F. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal, 2011, Vol. 4, no. 162, ra12. doi: 10.1126/scisignal.2001270.
91. Schingnitz U., Hartmann K., Macmanus C.F., Eckle T., Zug S., Colgan S.P., Eltzschig H.K. Signaling through the A2B Adenosine receptor dampens endotoxin-induced acute lung injury. J. Immunol., 2010, Vol. 184, no. 9, pp. 5271-5279.
92. Schuchardt M., Tolle M., Prufer J., Prufer N., Huang T., Jankowski V., Jankowski J., Zidek W., van der Giet M. Uridine adenosine tetraphosphate activation of the purinergic receptor P2Y enhances in vitro vascular calcification. Kidney Int., 2012, Vol. 81, pp. 256-265.
93. Stagg J., Smyth M.J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene, 2010, Vol. 29, no. 39, pp. 5346-5358.
94. Sullivan G.W., Fang G., Linden J., Scheld W.M. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J. Infect. Dis., 2004, Vol. 189, no. 10, pp. 1897-1904.
95. Sumi Y., Woehrle T., Chen Y., Bao Y., Li X., Yao Y., Inoue Y., Tanaka H., Junger W.G. Plasma ATP is required for neutrophil activation in a mouse sepsis model. Shock, 2014, Vol. 42, no. 2, pp. 142-147.
96. Surprenant A., North R.A. Signaling at purinergic P2X receptors. Annu Rev. Physiol., 2009, Vol. 71, no. 1, pp. 333-359.
97. Thompson L.F., Tsukamoto H., Chernogorova P., Zeiser R. A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs tumor. Oncoimmunology, 2013, Vol. 2, no. 1, e22107. doi:10.4161/onci.22107.
98. Trabanelli S., Očadlíková D., Gulinelli S., Curti A., Salvestrini V., de Paula Vieira R., Idzko M., Di Virgilio F., Ferrari D., Lemoli R.M. Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. J. Immunol., 2012, Vol. 189, no. 3, pp. 1303-1310.
99. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol., 2010, Vol. 10, no. 3, pp. 210-215.
100. Tsukamoto H., Chernogorova P., Ayata K., Gerlach U.V., Rughani A., Ritchey J.W., Ganesan J., Follo M., Zeiser R., Thompson L.F., Idzko M. Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versushost disease. Blood, 2012, Vol. 119, no. 19, pp. 4554-4564.
101. Wang L., Fan J., Chen S., Zhang Y., Curiel T.J., Zhang B. Graft-versus-host disease is enhanced by selective CD73 blockade in mice. Eckle T., ed. PLoS ONE, 2013, Vol. 8, no. 3, e58397. doi:10.1371/journal.pone.0058397.
102. Whiteside T.L. Targeting adenosine in cancer immunotherapy: a review of recent progress. Expert. Rev. Anticancer. Ther., 2017, Vol. 17, no. 6, pp. 527-535.
103. Winchester R., Wiesendanger M., O’Brien W., Zhang H.-Z., Maurer M.S., Gillam L.D., Schwartz A., Marboe C., Stewart A.S. Circulating Activated and effector memory T cells are associated with calcification and clonal expansions in bicuspid and tricuspid valves of calcific aortic stenosis. J. Immunol., 2011, Vol. 187, no. 2, pp. 1006-1014.
104. Woehrle T., Yip L., Elkhal A., Sumi Y., Chen Y., Yao Y., Insel P.A., Junger W.G. Pannexin-1 hemichannel– mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood, 2010, Vol. 116, pp. 3475-3484.
105. Xing S., Grol M.W., Grutter P.H., Dixon S.J., Komarova S.V. Modeling interactions among individual P2 receptors to explain complex response patterns over a wide range of ATP concentrations. Front. Physiol., 2016, Vol. 7, 294. doi: 10.3389/fphys.2016.00294.
106. Yaron J.R., Gangaraju S., Rao M.Y., Kong X., Zhang L., Su F., Tian Y., Glenn H.L., Meldrum D.R. K+regulates Ca2+ to drive inflammasome signaling: dynamic visualization of ion flux in live cells. Cell Death Dis., 2015, Vol. 6, e1954. doi: 10.1038/cddis.2015.277.
107. Yegutkin G.G. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta, 2008, Vol. 1783, no. 5, pp. 673-694.
108. Yip L., Woehrle T., Corriden R., Hirsh M., Chen Y., Inoue Y., Ferrari V., Insel P.A., Junger W.G. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J., 2009, Vol. 23, no. 6, pp. 1685-1693.
Рецензия
Для цитирования:
Головкин А.С., Асадуллина И.А., Кудрявцев И.В. ПУРИНЕРГИЧЕСКАЯ РЕГУЛЯЦИЯ ОСНОВНЫХ ФИЗИОЛОГИЧЕСКИХ И ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ. Медицинская иммунология. 2018;20(4):463-476. https://doi.org/10.15789/1563-0625-2018-4-463-476
For citation:
Golovkin A.S., Asadullina I.A., Kudryavtsev I.V. PURINERGIC REGULATION OF BASIC PHYSIOLOGICAL AND PATHOLOGICAL PROCESSES. Medical Immunology (Russia). 2018;20(4):463-476. (In Russ.) https://doi.org/10.15789/1563-0625-2018-4-463-476
Просмотров:
1302
Послать статью по эл. почте 